At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3084077 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Placebo and LY3084077 for Healthy Volunteers. Completed, enrolled 43 participants across 1 site.
Detailed Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3084077 in healthy participants. The study will also investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study is expected to last approximately 8 weeks for each participant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedMay 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedMay 3, 2013
Enrollment StartMay 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.2 years ago
Interventions
Placebodrug
Given as a SC injection.
LY3084077drug
Given as a SC injection.